Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that ...

GLP-1s exploded seemingly out of nowhere, straining pharmacy plan bottom lines. Psoriasis treatments don't have to follow the ...

TNF Pharmaceuticals and Renova Health are set to use AI and machine learning for the identification of high-risk subjects who ...

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

Chronic lower respiratory diseases, namely, asthma and chronic obstructive pulmonary disease , are the fifth-leading cause of ...

The trial recruited patients across a wide spectrum of COPD phenotypes and clinical presentations ... offers a clinically meaningful benefit to a patient population in need of treatments to reduce ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Advanced Treatments Create New Prospects for Patients and Their Healthcare Providers New FDA-approved medical treatments can be transformative for patients and families, often providing them with more ...

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine. The FDA is reviewing the BLA for mepolizumab, an interleukin-5 ...

Pulmonologists share best practices on when primary care providers should consider sending patients with respiratory ...